Endocan Levels at Polycystic Ovary Syndrome and Periodontal Inflammation

Ebru Saglam

Status: Completed

Conditions: Polycystic Ovary Syndrome; Cytokines; Inflammation Gum

Treatments: Diagnostic Test: Collection of Serum and Saliva Samples

Study type: Observational

Funder types: Other

Identifiers

NCT03264846

EbSAGLAM1

Details and patient eligibility

About

Periodontal diseases are chronic inflammatory disease occurred by the interaction between pathogenic microorganism and the host defense. Polycystic ovary syndrome (PCOS) is a reproductive and metabolic disease associated with increased risk of cardiovascular events. Endocan is a proteoglycan secreted mainly by endothelial cells under the control of inflammatory cytokines.

Periodontal diseases, including gingivitis, are common chronic infectious diseases caused by predominantly pathogenic microorganisms that colonize the subgingival area and cause local and systemic elevations of proinflammatory cytokines such as Interleukin-6 (IL-6).

Several lines of evidence established the association between periodontal and systemic diseases, including metabolic syndrome, diabetes, and cardiovascular disease.

Because of the fact that both periodontal disease and PCOS are associated with systemic inflammation and insulin resistance, these two disorders may be linked through a common pathophysiologic pathway.

A number of studies have indicated a possible relationship between PCOS and periodontal inflammation. Despite common risk factors, including oxidative stress, the relationship between chronic periodontitis (CP) and PCOS remains unclear.

The aims of the study were to determine serum and saliva Endocan and IL-6 levels and to evaluate the correlation between these two biomarker in women with periodontal disease and PCOS.

Enrollment: 87 patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Newly diagnosed PCOS patients
• Never smokers
• Had no history of systemic disease
• BMI<25 kg/m2
• Participants had ≥20 teeth present.

Exclusion criteria

• Pregnancy
• Lactation
• Hemoglobin A1c (HbA1c) ≥ 6.5%
• 2-h oral glucose tolerance test (OGTT-2h) ≥200
• Cushing syndrome, non-classic congenital adrenal hyperplasia, hyperprolactinemia, thyroid dysfunction, and androgen-secreting tumors
• Using antibiotics and antiinflammatory within the past 6 months
• Periodontal treatment within the past 6 months

Trial design

87 participants in 4 patient groups

Group 1

Description:

PCOS participants with periodontitis

Treatment:

Diagnostic Test: Collection of Serum and Saliva Samples

Group 2

Description:

PCOS participants with periodontally healthy

Treatment:

Diagnostic Test: Collection of Serum and Saliva Samples

Group 3

Description:

systemically healthy participants with periodontitis

Treatment:

Diagnostic Test: Collection of Serum and Saliva Samples

Group 4

Description:

systemically and periodontally healthy participants

Treatment:

Diagnostic Test: Collection of Serum and Saliva Samples